葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

交易中 02-13 10:51:25 EST

58.82

+0.28

+0.48%

最高59.11	最低58.57	成交量141.85万
今开58.88	昨收58.54	日振幅0.91%
总市值1,199亿	流通市值1,145亿	总股本20.38亿
成交额8,345万	换手率0.07%	流通股本19.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":58.82,"timestamp":1770997884577,"preClose":58.54,"halted":0,"volume":1418488,"delay":0,"changeRate":0.004783054321831246,"floatShares":1946891708,"shares":2037944753,"eps":3.736205,"marketStatus":"交易中","change":0.28,"latestTime":"02-13 10:51:25 EST","open":58.88,"high":59.105,"low":58.57,"amount":83452205.155376,"amplitude":0.009139,"askPrice":58.82,"askSize":120,"bidPrice":58.81,"bidSize":347,"shortable":3,"etf":0,"ttmEps":3.736205,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771016400000},"marketStatusCode":2,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":58.54,"dividendRate":0.029633,"preHourTrading":{"tag":"盘前","latestPrice":58.83,"preClose":58.54,"latestTime":"09:29 EST","volume":43985,"amount":2584097.7691550003,"timestamp":1770992999042,"change":0.29,"changeRate":0.004954,"amplitude":0.009224},"postHourTrading":{"tag":"盘后","latestPrice":58.56,"preClose":58.54,"latestTime":"19:03 EST","volume":60553,"amount":3544754.0685,"timestamp":1770941016404,"change":0.02,"changeRate":0.000342,"amplitude":0.001877},"volumeRatio":0.866709,"impliedVol":0.3378,"impliedVolPercentile":0.8725},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"2610642029","title":"国家药监局受理葛兰素史克重组呼吸道合胞病毒疫苗60岁及以上成人适应症的上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2610642029","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610642029?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:12","pubTimestamp":1770725567,"startTime":"0","endTime":"0","summary":"南方财经2月10日电，葛兰素史克（LSE/NYSE:GSK）宣布，中国国家药品监督管理局（NMPA）药品审评中心（CDE）已受理其重组呼吸道合胞病毒疫苗（CHO细胞，AS01E佐剂系统）的上市申请，该疫苗用于60岁及以上的成人预防由RSV引起的下呼吸道疾病（LRTD）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646856626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","BK4585","BK4007","LU1829250122.USD","BK4532","GSK.UK","BK4588","GSK"],"gpt_icon":0},{"id":"2610895456","title":"花旗：将葛兰素史克目标价提高至2250便士","url":"https://stock-news.laohu8.com/highlight/detail?id=2610895456","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610895456?lang=zh_cn&edition=full","pubTime":"2026-02-09 14:27","pubTimestamp":1770618421,"startTime":"0","endTime":"0","summary":"花旗集团将葛兰素史克目标股价从1900便士提高至2250便士。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260209/32007202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["GSK"],"gpt_icon":0},{"id":"2609154718","title":"葛兰素史克2025财年实现净利润75.33亿美元，同比增加128.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609154718","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609154718?lang=zh_cn&edition=full","pubTime":"2026-02-07 00:01","pubTimestamp":1770393679,"startTime":"0","endTime":"0","summary":"2月7日，葛兰素史克公布财报，公告显示公司2025财年净利润为75.33亿美元，同比增加128.97%；其中营业收入为430.52亿美元，同比增加7.38%，每股基本收益为3.72美元。从资产负债表来看，葛兰素史克总负债606.55亿美元，其中短期债务40.51亿美元，资产负债比为1.36，流动比率为0.82。机构评级：截至2026年2月7日，当前有3家机构对葛兰素史克目标价做出预测，其中目标均价为51.10美元，其中最低目标价为48.30美元，最高目标价为55.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000126a6dc451b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000126a6dc451b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GSK"],"gpt_icon":0},{"id":"2609596419","title":"葛兰素史克(GSK)：欧盟委员会批准Nucala用于未受控的慢性阻塞性肺病","url":"https://stock-news.laohu8.com/highlight/detail?id=2609596419","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609596419?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:29","pubTimestamp":1770384564,"startTime":"0","endTime":"0","summary":"金吾财讯 | 葛兰素史克(GSK)宣布，欧盟委员会已批准其单克隆抗体维持治疗药物Nucala用于未受控的慢性阻塞性肺病。该批准基于MATINEE III期试验的积极数据，其中在广泛具有嗜酸性粒细胞表型的COPD患者中，mepolizumab与安慰剂加标准护理相比，显示出在中度/重度急性加重年化率上的临床意义和统计学显著降低。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/N2I5NmMxMDRhMjE5ZjZkNDA5NWY5Njk1NzgzMjA0MDcxNDc1OTcyMzk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/N2I5NmMxMDRhMjE5ZjZkNDA5NWY5Njk1NzgzMjA0MDcxNDc1OTcyMzk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"296967","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1829250122.USD","GSK.UK","BK4588","BK4532","GSK","BK4585"],"gpt_icon":0},{"id":"2609961275","title":"葛兰素史克慢阻肺药物Nucala获欧盟批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2609961275","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609961275?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:26","pubTimestamp":1770384368,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["FESXmain","GSK","LU1829250122.USD","BK4007","BK4532","BK4588","BK4585","FSXEmain","GSK.UK"],"gpt_icon":0},{"id":"2609530156","title":"广誉远聘任75后王鹏浩为副总裁，履历涵盖哈药股份、葛兰素史克","url":"https://stock-news.laohu8.com/highlight/detail?id=2609530156","media":"瑞财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609530156?lang=zh_cn&edition=full","pubTime":"2026-02-06 09:48","pubTimestamp":1770342509,"startTime":"0","endTime":"0","summary":"瑞财经 刘治颖2月2日，广誉远公告，董事会同意聘任王鹏浩为公司副总裁，任期自本次董事会决议生效之日起至选举产生新一届董事会之日止。王鹏浩，出生于1975年5月，工商企业管理学士。广誉远成立于1996-11-25，法定代表人为李晓军，注册资本为4.89亿元，主要从事中药产品的生产与销售。该公司大股东为神农科技集团有限公司，持股15.17%。2025年前三季度，广誉远营业收入为10.61亿元，同比上升18.71%；归母净利润为7888.4万元，同比上升11.16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206094833a6d95257&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206094833a6d95257&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","GSK.UK","GSK","BK4532","LU1829250122.USD","BK4007","BK4588"],"gpt_icon":0},{"id":"2609530905","title":"GSK新帅上任，开启“精细化”研发与并购新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2609530905","media":"MedTrend医趋势","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609530905?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:05","pubTimestamp":1770282356,"startTime":"0","endTime":"0","summary":"GSK新任CEO Luke Miels在接替Emma Walmsley后，首次明确了他的管理风格：更激进的外部并购、更严苛的管线审查，以及向“以产品为中心”的转型。并购策略：寻找“隐藏在众目睽睽”的机会Miels 明确了GSK未来的交易逻辑，重点不再是单纯的大规模收购，而是精准的“补强型”收购，理想的交易范围在20亿-40亿美元之间。近日，GSK确认将在英国和美国裁减数百名研发人员，旨在精简组织架构。2026 年，处于转型期的GSK销售预计增长3%-5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205195933a4802856&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205195933a4802856&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","BK4588","BK4585","GSK.UK","GSK","BK4532","BK4007"],"gpt_icon":0},{"id":"2609326927","title":"红斑狼疮新疗法有望惠及中国百万患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2609326927","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609326927?lang=zh_cn&edition=full","pubTime":"2026-02-05 15:09","pubTimestamp":1770275344,"startTime":"0","endTime":"0","summary":"系统性红斑狼疮（SLE）作为一种自身免疫性疾病，目前尚无法治愈。长期以来，针对该疾病的创新疗法也备受关注。近日，阿斯利康公司一款治疗系统性红斑狼疮的生物制剂阿伏利尤单抗（anifrolumab）的三期临床试验结果显示，针对亚洲成年中重度系统性红斑狼疮患者，与安慰剂组相比，在降低疾病活动度和减少口服糖皮质激素用量方面均显示出统计学和临床意义上的改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642699418.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642699418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","GSK","BK4007","BK4588","BK4077","SLE","BK4532","LU1829250122.USD","BK4585"],"gpt_icon":0},{"id":"2608424393","title":"美股异动丨葛兰素史克涨超7%创新高，去年净利润同比翻倍+提高年度股息","url":"https://stock-news.laohu8.com/highlight/detail?id=2608424393","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608424393?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:13","pubTimestamp":1770217989,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["TWM","UWM","RWM","BK4581","BK4535","BK4532","TNA","BK4007","BK4585","MNQmain","IWN","IWO","BK4588","BK4534","SRTY","BK4550","GSK.UK","TZA","GSK","LU1829250122.USD"],"gpt_icon":0},{"id":"1166696259","title":"异动解读 | Q4盈利超预期叠加积极业绩指引，葛兰素史克盘中大涨6.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166696259","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166696259?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:00","pubTimestamp":1770217231,"startTime":"0","endTime":"0","summary":"葛兰素史克今日盘中股价大幅上涨6.43%，引起了市场的广泛关注。此外，公司给出了2026年利润增长7%至9%的积极指引，高于部分分析师此前预期的6%至8%，增强了投资者对公司未来业绩的信心。尽管公司面临部分药物专利到期等挑战，但其专科药物业务预计将实现低两位数增长，稳健的业绩表现和清晰的未来规划是推动股价在盘中交易时段走强的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GSK"],"gpt_icon":0},{"id":"1141224239","title":"异动解读 | Q4盈利超预期，葛兰素史克盘前大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141224239","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141224239?lang=zh_cn&edition=full","pubTime":"2026-02-04 19:35","pubTimestamp":1770204921,"startTime":"0","endTime":"0","summary":"英国制药巨头葛兰素史克今日盘前股价大幅上涨5.02%，引起了市场的广泛关注。消息面上，该公司最新发布的第四季度财报显示，其利润超出市场预期，这主要得益于其艾滋病药物以及一款用于治疗肺部疾病的哮喘药物的强劲表现。尽管公司面临部分药物专利到期等挑战，但其专科药物业务预计将实现低两位数增长，稳健的业绩表现和清晰的未来规划是推动股价在盘前交易时段走强的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GSK"],"gpt_icon":0},{"id":"2608359152","title":"艾滋病药物发力提振业绩 葛兰素史克(GSK.US)Q4利润超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608359152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608359152?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:40","pubTimestamp":1770194428,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克第四季度利润高于预期，这主要得益于其艾滋病药物以及一款现已获批用于治疗肺部疾病的哮喘药物。葛兰素史克预计 2026 年营业额增长 3% 至 5%；核心营业利润增长 7% 至 9%；核心每股收益增长 7% 至 9%。葛兰素史克目前正面临其最畅销艾滋病药物重大的“专利悬崖”。该组合由艾滋病、癌症药物以及 Nucala 等药物组成，其中 Nucala 已在美国获批用于治疗慢性阻塞性肺疾病，这是一种严重的肺部疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1829250122.USD","BK4585","BK4588","BK4532","BK4007","GSK.UK","GSK"],"gpt_icon":0},{"id":"1152418139","title":"财报前瞻｜葛兰素史克本季度营收预计增17.57%，多机构维持偏积极判断","url":"https://stock-news.laohu8.com/highlight/detail?id=1152418139","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152418139?lang=zh_cn&edition=full","pubTime":"2026-01-28 10:09","pubTimestamp":1769566189,"startTime":"0","endTime":"0","summary":"葛兰素史克将于2026年02月04日发布最新季度财报，市场预期营收和每股收益同比提升，机构将关注疫苗与专科药的持续动能。市场一致预期本季度总收入为113.77亿美元，同比增17.57%；EPS为0.63美元，同比增43.68%；EBIT为19.04亿美元，同比增11.66%；公司此前指引强调核心板块稳健，但未披露本季度毛利率与净利率的量化展望。上季度公司实现营收85.47亿美元，毛利率73.86%，归属母公司净利润20.13亿美元，同比增长39.50%，净利率23.55%，调整后每股收益1.48美元，同比增长14.78%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜葛兰素史克本季度营收预计增17.57%，多机构维持偏积极判断","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"gpt_icon":0},{"id":"2606218216","title":"葛兰素史克(GSK)Arexvy疫苗获欧盟批准用于所有成人","url":"https://stock-news.laohu8.com/highlight/detail?id=2606218216","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606218216?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:41","pubTimestamp":1769416877,"startTime":"0","endTime":"0","summary":"金吾财讯 | 葛兰素史克(GSK)宣布，欧盟委员会已批准其呼吸道合胞病毒疫苗Arexvy用于18岁及以上成人。该疫苗此前已获准用于50至59岁呼吸道合胞病毒感染风险增加的成人，以及60岁及以上人群。葛兰素史克表示，公司正继续在美国和日本寻求扩大其呼吸道合胞病毒疫苗的适应症范围。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NWE0NDM0MDU5NDk3NzI5.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWE0NDM0MDU5NDk3NzI5.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"296556","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSXEmain","BK4007","FESXmain","159646","BK4532","BK4585","LU1829250122.USD","GSK","BK4588","GSK.UK"],"gpt_icon":0},{"id":"2606122293","title":"3万亿赛道的估值锚点，彻底变了","url":"https://stock-news.laohu8.com/highlight/detail?id=2606122293","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606122293?lang=zh_cn&edition=full","pubTime":"2026-01-26 08:12","pubTimestamp":1769386320,"startTime":"0","endTime":"0","summary":"多只创新药ETF的年内最高涨幅突破50%，多家创新药企股价翻番。不过，我们发现经过验证的靶点，不同企业的BD交易授权下，资本市场也给出了不同反应。且2024年，美国FDA批准了同类首款药物Ensifentrine，为该靶点的成药性提供了关键验证。只不过与海思科不同，恒瑞医药在与GSK的交易公告后，其A股和H股股价均出现了显著上涨。据悉，恒瑞医药获得的5亿美元为纯现金首付款，可以立即确认业绩，展现了GSK对其资产价值的强烈认可和信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656147805&idx=1&sn=bc6bcda7f82ce0193ae3a090ba46cdc8&chksm=67838d5482c3a023e3be79b5567544c3a508a60a147222d217af39c881d77ba875ce4eab9a04&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1583","09995","LU2148510915.USD","LU1969619763.USD","GSK.UK","BK1574","BK4007","AA","688331","BK4532","LU1064131003.USD","LU1064130708.USD","GSK","BK4585","BK1161","BK0239","LU1829250122.USD","LU2488822045.USD","LU2328871848.SGD","BK4153","BK4588","06978"],"gpt_icon":0},{"id":"2605342711","title":"“全再乐”新增适应症在中国获批 用于成人哮喘患者维持治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2605342711","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605342711?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:07","pubTimestamp":1769155648,"startTime":"0","endTime":"0","summary":"中国网财经1月23日讯葛兰素史克(LSE/NYSE:GSK)今日宣布，国家药品监督管理局(NMPA)已批准全再乐(氟替美维吸入粉雾剂，FF/UMEC/VI)新增适应症，用于成人哮喘患者的维持治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601233628857245.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233628857245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","GSK.UK","BK4588","LU1829250122.USD","GSK","BK4585","BK4007"],"gpt_icon":0},{"id":"2605424201","title":"葛兰素史克全再乐在中国获批用于成人哮喘患者的维持治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2605424201","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605424201?lang=zh_cn&edition=full","pubTime":"2026-01-23 15:30","pubTimestamp":1769153459,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4007","LU1829250122.USD","BK4532","GSK.UK","BK4588","GSK"],"gpt_icon":0},{"id":"2604837114","title":"英国葛兰素史克（GSK）股价上涨63.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604837114","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604837114?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:40","pubTimestamp":1768920001,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月20日，英国葛兰素史克（GSK）将以22亿美元收购RAPT治疗公司后，该公司股价上涨63.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601203625019852.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203625019852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4007","LU1829250122.USD","GSK.UK","BK4588","GSK","BK4532"],"gpt_icon":0},{"id":"2604113507","title":"GSK 达成一笔 22 亿美元的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113507","media":"丁香园 Insight 数据库","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604113507?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:23","pubTimestamp":1768897383,"startTime":"0","endTime":"0","summary":"1 月 20 日，GSK 宣布已达成最终协议，收购 RAPT Therapeutics。截图来源：企业官网根据协议条款，GSK 将在交易完成时向 RAPT Therapeutics 股东支付每股 58.00 美元，预计总股权价值为22 亿美元。扣除收购的现金后，GSK 预计的前期投资为 19 亿美元。此次交易使GSK 获得 Ozureprubart 项目的全球权益，但不包括中国大陆、澳门、台湾和香港地区。GSK 还将负责向 RAPT 的合作伙伴济民可信支付Ozureprubart项目基于成功研发的里程碑付款和特许权使用费。该交易预计将于 2026 年第一季度完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120171645a4405fbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120171645a4405fbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","RAPT","LU1829250122.USD","GSK","BK4532","GSK.UK","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2604167450","title":"葛兰素史克将收购生物制药公司RAPT","url":"https://stock-news.laohu8.com/highlight/detail?id=2604167450","media":"南方财经网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604167450?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:36","pubTimestamp":1768894560,"startTime":"0","endTime":"0","summary":"南方财经1月20日电，据界面新闻，葛兰素史克1月20日宣布，已同RAPTTherapeutics达成最终收购协议。RAPT是一家位于美国加州的临床阶段生物制药公司，致力于为患有炎症和免疫疾病的患者开发新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b0ae671786534a1c4e2be67b7d225de0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624628683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","GSK","RAPT","BK4588","GSK.UK","BK4585","BK4007","LU1829250122.USD","BK4532"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":-0.0106},{"period":"1month","weight":0.1731},{"period":"3month","weight":0.2408},{"period":"6month","weight":0.4873},{"period":"1year","weight":0.6203},{"period":"ytd","weight":0.1937}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由 Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.013809},{"month":2,"riseRate":0.478261,"avgChangeRate":0.000995},{"month":3,"riseRate":0.622222,"avgChangeRate":0.021018},{"month":4,"riseRate":0.673913,"avgChangeRate":0.032633},{"month":5,"riseRate":0.413043,"avgChangeRate":-0.008096},{"month":6,"riseRate":0.586957,"avgChangeRate":0.009648},{"month":7,"riseRate":0.543478,"avgChangeRate":0.003945},{"month":8,"riseRate":0.586957,"avgChangeRate":0.005806},{"month":9,"riseRate":0.521739,"avgChangeRate":0.005973},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013062},{"month":11,"riseRate":0.478261,"avgChangeRate":0.009917},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014188}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}